Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts

Toxicology

Volumn 258, Issue 2-3, 2009, Pages 148-156

  Chang, Je Ken ^a,c   Li, Ching Ju ^a   Liao, Hsiu Jun ^a   Wang, Chih Kuang ^a,b   Wang, Gwo Jaw ^a,c   Ho, Mei Ling ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Anti inflammatory drugs; Apoptosis; Cell cycle regulator; Human osteoblasts; Proliferation

Indexed keywords

CELECOXIB; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEXAMETHASONE; DICLOFENAC; INDOMETACIN; KETOROLAC; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROTEIN BAK; PROTEIN BCL XL;

ADULT; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION;

ANNEXIN A5; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2 INHIBITORS; DEXAMETHASONE; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOHISTOCHEMISTRY; INDOMETHACIN; KETOROLAC; L-LACTATE DEHYDROGENASE; OSTEOBLASTS; PIROXICAM; PROPIDIUM; PYRAZOLES; RNA, MESSENGER; SULFONAMIDES; THYMIDINE;

ANIMALIA; RATTUS;

EID: 61349136212     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.01.016     Document Type: Article

References (51)

1. Arellano M., and Moreno S. Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol. 2 (1997) 559-573
2. Basu A., and Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol. Hum. Reprod. 4 (1998) 1099-1109
3. Bauer D.C., Orwoll E.S., Fox K.M., Vogt T.M., Lane N.E., Hochberg M.C., Stone K., and Nevitt M.C. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11 (1996) 29-35
4. Blocka K.L., Richardson C.J., Wallace S.M., Ross S.G., and Verbeeck R.K. The effect of age on piroxicam disposition in rheumatoid arthritis. J. Rheumatol. 15 (1988) 757-763
5. Buckley M.M., and Brogden R.N. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 39 (1990) 86-109
6. Carbone L.D., Tylavsky F.A., Cauley J.A., Harris T.B., Lang T.F., Bauer D.C., Barrow K.D., and Kritchevsky S.B. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J. Bone Miner. Res. 18 (2003) 1795-1802
7. Chang J.K., Wang G.J., Tsai S.T., and Ho M.L. Nonsteroidal anti-inflammatory drug effects on osteoblastic cell cycle, cytotoxicity, and cell death. Connect. Tissue Res. 46 (2005) 200-210
8. Chang J.K., Wu S.C., Wang G.J., Cho M.H., and Ho M.L. Effects of non-steroidal anti-inflammatory drugs on cell proliferation and death in cultured epiphyseal-articular chondrocytes of fetal rats. Toxicology 228 (2006) 111-123
9. Chang J.K., Ho M.L., Yeh C.H., Chen C.H., and Wang G.J. Osteogenic gene expression decreases in stromal cells of patients with osteonecrosis. Clin. Orthop. Relat. Res. 453 (2006) 286-292
10. Chang J.K., Li C.J., Wu S.C., Yeh C.H., Chen C.H., Fu Y.C., Wang G.J., and Ho M.L. Effects of anti-inflammatory drugs on proliferation, cytotoxicity and osteogenesis in bone marrow mesenchymal stem cells. Biochem. Pharmacol. 74 (2007) 1371-1382
11. Clemett D., and Goa K.L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59 (2000) 957-980
12. Cooper C., Coupland C., and Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann. Rheum. Dis. 54 (1995) 49-52
13. Corroyer S., Schittny J.C., Djonov V., Burri P.H., and Clement A. Impairment of rat postnatal lung alveolar development by glucocorticoids: involvement of the p21CIP1 and p27KIP1 cyclin-dependent kinase inhibitors. Pediatr. Res. 51 (2002) 169-176
14. Fernandes D., Guida E., Koutsoubos V., Harris T., Vadiveloo P., Wilson J.W., and Stewart A.G. Glucocorticoids inhibit proliferation, cyclin D1 expression, and retinoblastoma protein phosphorylation, but not activity of the extracellular-regulated kinases in human cultured airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 21 (1999) 77-88
15. Gerstenfeld L.C., and Einhorn T.A. COX inhibitors and their effects on bone healing. Expert Opin. Drug Saf. 3 (2004) 131-136
16. Gerstenfeld L.C., Al-Ghawas M., Alkhiary Y.M., Cullinane D.M., Krall E.A., Fitch J.L., Webb E.G., Thiede M.A., and Einhorn T.A. Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing, Reversibility of effects after short-term treatment. J. Bone Joint Surg. Am. 89 (2007) 114-125
17. Goldberg Y., Nassif I.I., Pittas A., Tsai L.L., Dynlacht B.D., Rigas B., and Shiff S.J. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12 (1996) 893-901
18. Goodman S., Ma T., Trindade M., Ikenoue T., Matsuura I., Wong N., Fox N., Genovese M., Regula D., and Smith R.L. COX-2 selective NSAID decreases bone ingrowth in vivo. J. Orthop. Res. 20 (2002) 1164-1169
19. Grosch S., Tegeder I., Niederberger E., Brautigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15 (2001) 2742-2744
20. Hakeda Y., Yoshino T., Natakani Y., Kurihara N., Maeda N., and Kumegawa M. Prostaglandin E2 stimulates DNA synthesis by a cyclic AMP-independent pathway in osteoblastic clone MC3T3-E1 cells. J. Cell. Physiol. 128 (1986) 155-161
21. Harder A.T., and An Y.H. The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review. J. Clin. Pharmacol. 43 (2003) 807-815
22. Hatakeyama M., and Weinberg R.A. The role of RB in cell cycle control. Prog. Cell Cycle Res. 1 (1995) 9-19
23. Ho M.L., Chang J.K., and Wang G.J. Antiinflammatory drug effects on bone repair and remodeling in rabbits. Clin. Orthop. (1995) 270-278
24. Ho M.L., Chang J.K., and Wang G.J. Effects of ketorolac on bone repair: a radiographic study in modeled demineralized bone matrix grafted rabbits. Pharmacology 57 (1998) 148-159
25. Ho M.L., Chang J.K., Chuang L.Y., Hsu H.K., and Wang G.J. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. Biochem. Pharmacol. 58 (1999) 983-990
26. Kawaguchi H., Pilbeam C.C., Harrison J.R., and Raisz L.G. The role of prostaglandins in the regulation of bone metabolism. Clin. Orthop. 313 (1995) 36-46
27. Kovarik J.M., Purba H.S., Pongowski M., Gerbeau C., Humbert H., and Mueller E.A. Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. Pharmacotherapy 18 (1998) 1230-1236
28. Krischak G.D., Augat P., Blakytny R., Claes L., Kinzl L., and Beck A. The non-steroidal anti-inflammatory drug diclofenac reduces appearance of osteoblasts in bone defect healing in rats. Arch. Orthop. Trauma Surg. 127 (2007) 453-458
29. Lane N.E., Bauer D.C., Nevitt M.C., Pressman A.R., and Cummings S.R. Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research Group. J. Rheumatol. 24 (1997) 1132-1136
30. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
31. Morton D.J., Barrett-Connor E.L., and Schneider D.L. Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. J. Bone Miner. Res. 13 (1998) 1924-1931
32. Niculescu III A.B., Chen X., Smeets M., Hengst L., Prives C., and Reed S.I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 18 (1998) 629-643
33. Oberbauer R., Krivanek P., and Turnheim K. Pharmacokinetics of indomethacin in the elderly. Clin. Pharmacokinet. 24 (1993) 428-434
34. Piazza G.A., Rahm A.K., Finn T.S., Fryer B.H., Li H., Stoumen A.L., Pamukcu R., and Ahnen D.J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57 (1997) 2452-2459
35. Pilbeam C.C., Raisz L.G., Voznesensky O., Alander C.B., Delman B.N., and Kawaguchi H. Autoregulation of inducible prostaglandin G/H synthase in osteoblastic cells by prostaglandins. J. Bone Miner. Res. 10 (1995) 406-414
36. Radi Z.A., and Khan N.K. Effects of cyclooxygenase inhibition on bone, tendon, and ligament healing. Inflamm. Res. 54 (2005) 358-366
37. Raisz L.G. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 7 (1999) 419-421
38. Richards J.B., Joseph L., Schwartzman K., Kreiger N., Tenenhouse A., and Goltzman D. The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study. Osteoporos. Int. 17 (2006) 1410-1419
39. Saag K.G., Koehnke R., Caldwell J.R., Brasington R., Burmeister L.F., Zimmerman B., Kohler J.A., and Furst D.E. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am. J. Med. 96 (1994) 115-123
40. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
41. Shiff S.J., Koutsos M.I., Qiao L., and Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp. Cell Res. 222 (1996) 179-188
42. Simon A.M., and O'Connor J.P. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J. Bone Joint Surg. Am. 89 (2007) 500-511
43. Suzuki N., and Hattori A. Bisphenol A suppresses osteoclastic and osteoblastic activities in the cultured scales of goldfish. Life Sci. 73 (2003) 2237-2247
44. Todd P.A., and Sorkin E.M. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 35 (1988) 244-285
45. Verstraeten A., and Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann. Rheum. Dis. 45 (1986) 852-857
46. Viereck V., Grundker C., Blaschke S., Niederkleine B., Siggelkow H., Frosch K.H., Raddatz D., Emons G., and Hofbauer L.C. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J. Clin. Endocrinol. Metab. 88 (2003) 4206-4213
47. Vrotsos Y., Miller S.C., and Marks Jr. S.C. Prostaglandin E-a powerful anabolic agent for generalized or site-specific bone formation. Crit. Rev. Eukaryot. Gene Expr. 13 (2003) 255-263
48. Vuolteenaho K., Moilanen T., and Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin. Pharmacol. Toxicol. 102 (2008) 10-14
49. Weinstein R.S., and Manolagas S.C. Apoptosis and osteoporosis. Am. J. Med. 108 (2000) 153-164
50. Weinstein R.S., Jilka R.L., Parfitt A.M., and Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102 (1998) 274-282
51. Zhang G., Tu C., Zhou G., and Zheng W. Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leuk. Res. 24 (2000) 385-392